Fig. 2: Targeted deletion of Irgm1 decreases OVX-induced bone loss.
From: Targeting Irgm1 to combat osteoporosis: suppressing ROS and restoring bone remodeling
A Genotype analysis for Irgm1. B RT-qPCR demonstrated the mRNA levels of Irgm1 in BMDMs from Control and Irgm1-cKO mice. Quantitative data were normalized to GAPDH and presented as means ± SD (n = 3), ∗∗∗p < 0.001 vs the indicated groups. C WB analysis of Irgm1 level in BMDMs derived from Irgm1flox/flox (Control) and Irgm1flox/flox; Lyz2-Cre (Irgm1-cKO) mice. D Representative three-dimensional (3D) reconstructed CT images of the distal femur from 5-month-old mice. E Quantitative measurements of BV/TV, Tb. N, Tb. Th, and Tb.Sp. All data were presented as the mean ± SD (n = 4), ∗p < 0.05, ∗∗∗p < 0.001, and ns (not statistically significant) vs the indicated groups. F Representative images of haematoxylin and eosin (H&E) staining on paraffin-embedded femur sections of the distal femur from 5-month-old mice from different groups. Scale bar = 200 μm. G Representative images of Masson staining on paraffin-embedded femur sections of the distal femur from 5-month-old mice from different groups. Scale bar = 200 μm. H Representative images showed TRAP activity staining in femur sections in different groups. Scale bar in lower magnification = 200 μm, scale bar in higher magnification = 20 μm. I Quantitative analysis of the number of TRAP-positive cells in femoral sections of different groups (n = 3), ∗p < 0.05 and ns vs the indicated groups. J Calcein double labeling of mineral layers of the femur.
